EXTRANODAL NK/T-CELL LYMPHOMA
Clinical trials for EXTRANODAL NK/T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new EXTRANODAL NK/T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for EXTRANODAL NK/T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo shows promise against tough lymphoma
Disease control Not yet recruitingThis study tests whether adding the drug golidocitinib to standard chemotherapy and immunotherapy works better for advanced NK/T-cell lymphoma. About 40 adults with newly diagnosed, advanced disease will be split into two groups: one gets the new combo, the other gets standard tr…
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: WEI XU • Aim: Disease control
Last updated May 17, 2026 14:56 UTC
-
Lower radiation, same hope: new combo targets lymphoma side effects
Disease control Not yet recruitingThis study tests whether adding the drug selinexor to a lower dose of radiation can treat early-stage NK/T-cell lymphoma as effectively as standard high-dose radiation, but with fewer side effects. About 34 people who have not had prior treatment will receive chemotherapy first, …
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New combo therapy shows promise for rare blood cancer
Disease control Not yet recruitingThis study tests two drugs, tislelizumab and zeprumetostat, together in people with NK/T-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if the combination can shrink tumors and to find the safest dose. About 107 adults will take part, and…
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Rong Tao • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New hope for rare blood cancer: drug combo targets relapsed lymphoma
Disease control Not yet recruitingThis study tests whether adding the drug sugemalimab to standard chemotherapy can help people with a rare type of blood cancer (extranodal NK/T-cell lymphoma) that has returned or stopped responding to previous treatment. About 150 adults will receive either the combination or a …
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:52 UTC